23.11.23 | BCRT (BIH Center for Regenerative Therapies), Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Föhrer Str. 15, DE-13353 Berlin 09:00 a.m. – 03:00 p.m.
Multiple sclerosis (MS) can take many different forms, which is why it is sometimes called “the disease of a thousand faces.” MS is also complex and difficult to treat. Now, an international consortium headed by Charité – Universitätsmedizin Berlin…
Continuation of its European growth course – Expansion of services for manufacturers of medical devices - Integration of the use of Scandinavian medical registries
Some T cells of the immune system are especially sensitive to genetic disturbances within their mitochondrial power plants. Scientists from BIH and Max Delbrück Center have now published their findings in the journal “Nature Genetics”.
Researchers at the Max Planck Institute of Colloids and Interfaces (MPICI) have designed a carbohydrate sequence capable of folding into a stable secondary structure. Until now, such self-folding biopolymers had only been developed for DNA and…
Investigational Bemdaneprocel (BRT-DA01) was well tolerated with no major safety issues in all 12 patients through one year
Assessment of secondary endpoints demonstrates feasibility of transplantation and evidence of cell survival and engraftment …
At its annual meeting in Göttingen, the Max Planck Society awarded the Otto Hahn Medal 2022 to the young scientist Dr Susanne Reischauer. The prize is awarded for outstanding scientific achievements during doctoral studies.
Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund (PIF) based in Riyadh
JV focuses on providing state-of-the-art multiomic…
A new tool can identify cells that are actively responding to a SARS-CoV-2 infection. As reported in "Science Advances" by the Gargiulo lab, it can be used to screen for effective COVID-19 therapies and can be tailored to study other viruses as well.
OMEICOS, a biopharmaceutical company developing first-in-class small molecule therapeutics based on the profound understanding of omega-3 fatty acid metabolism and physiology, announced today that the Company has received a significant grant by the…
